Approval in the US of the second OTC product in a drug category typically doesn’t merit mention by the Food and Drug Administration commissioner.
Making opioid overdose treatment naloxone available OTC, however, isn’t a typical approval by the FDA.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?